Corrigendum to "Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway" [Biomed. Pharmacother. 180 (2024) 117589]

Jiaan Huang¹, Yan Liu¹, Mengting Shi², Xiaoyun Zhang³, Yan Zhong³, Shuai Guo⁴, Yun Ma⁵, Limin Pan⁵, Fan Yang⁶, Yuehua Wang⁷

Affiliations

¹ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China.
² Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Acupuncture and moxibustion and Massage College of Hebei University of Chinese Medicine, No.3 Xingyuan Road, Luquan District, Shijiazhuang 050200, China.
³ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China.
⁴ The Third Hospital of Hebei Medical University, Shijiazhuang 050200, China.
⁵ Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050200, China.
⁶ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China. Electronic address: yangfan001@hebcm.edu.cn.
⁷ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China; The Second Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Dingzhou 073000, China. Electronic address: wangyuehua@hebcm.edu.cn.

PMID: 40664589
DOI: 10.1016/j.biopha.2025.118321

Free article

Published Erratum

Corrigendum to "Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway" [Biomed. Pharmacother. 180 (2024) 117589]

Jiaan Huang et al. Biomed Pharmacother. 2025 Aug.

Free article

. 2025 Aug:189:118321.

doi: 10.1016/j.biopha.2025.118321. Epub 2025 Jul 15.

Authors

Jiaan Huang¹, Yan Liu¹, Mengting Shi², Xiaoyun Zhang³, Yan Zhong³, Shuai Guo⁴, Yun Ma⁵, Limin Pan⁵, Fan Yang⁶, Yuehua Wang⁷

Affiliations

¹ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China.
² Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Acupuncture and moxibustion and Massage College of Hebei University of Chinese Medicine, No.3 Xingyuan Road, Luquan District, Shijiazhuang 050200, China.
³ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China.
⁴ The Third Hospital of Hebei Medical University, Shijiazhuang 050200, China.
⁵ Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050200, China.
⁶ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China. Electronic address: yangfan001@hebcm.edu.cn.
⁷ Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Diseases, Shijiazhuang 05000, China; Hebei University of Traditional Chinese Medicine, No.326, Xinshi South Road, Qiaoxi District, Shijiazhuang 05000, China; The Second Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Dingzhou 073000, China. Electronic address: wangyuehua@hebcm.edu.cn.

PMID: 40664589
DOI: 10.1016/j.biopha.2025.118321

No abstract available

PubMed Disclaimer

Erratum for

Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway.
Huang J, Liu Y, Shi M, Zhang X, Zhong Y, Guo S, Ma Y, Pan L, Yang F, Wang Y. Huang J, et al. Biomed Pharmacother. 2024 Nov;180:117589. doi: 10.1016/j.biopha.2024.117589. Epub 2024 Oct 16. Biomed Pharmacother. 2024. PMID: 39418962

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway" [Biomed. Pharmacother. 180 (2024) 117589]

Affiliations

Corrigendum to "Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway" [Biomed. Pharmacother. 180 (2024) 117589]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous